CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
3.710
-0.110 (-2.88%)
Apr 28, 2026, 4:00 PM EDT - Market closed
CervoMed Employees
CervoMed had 15 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
15
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$267,101
Profits / Employee
-$1,797,758
Market Cap
34.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15 | 0 | - |
| Dec 31, 2024 | 15 | 7 | 87.50% |
| Dec 31, 2023 | 8 | 4 | 100.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Evaxion | 46 |
| NextCure | 40 |
| Senti Biosciences | 34 |
| Palatin Technologies | 29 |
| Boundless Bio | 28 |
| INmune Bio | 21 |
| Veru Inc. | 20 |
CRVO News
- 6 days ago - CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies - GlobeNewsWire
- 21 days ago - CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting - GlobeNewsWire
- 5 weeks ago - CervoMed Transcript: The 38th Annual Roth Conference - Transcripts
- 5 weeks ago - CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology - GlobeNewsWire
- 6 weeks ago - CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 7 weeks ago - CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies - GlobeNewsWire
- 2 months ago - CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors - GlobeNewsWire
- 5 months ago - CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - GlobeNewsWire